Results 201 to 210 of about 254,342 (304)
Editorial: Novel and promising laboratory biomarkers for allergic disease diagnosis and prognosis: clinical applicability. [PDF]
Velazquez-Soto H +2 more
europepmc +1 more source
Cryohydrocytosis: When Cold Breaks the Membrane
American Journal of Hematology, EarlyView.
Athina Ntoumaziou +5 more
wiley +1 more source
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
Bronchial thermoplasty for severe asthma: Systematic review and meta-analysis of benefits and harms. [PDF]
Rayner DG +34 more
europepmc +1 more source
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson +8 more
wiley +1 more source
Widening access to penicillin allergy assessment in the United Kingdom-a proposed implementation plan for the National Health Service (NHS). [PDF]
Porter CE +18 more
europepmc +1 more source
Peripheral Blood Erythrophagocytosis in Plasmodium falciparum Malaria
American Journal of Hematology, EarlyView.
Teresa Almeida, Cristina Avelar Ferreira
wiley +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1. [PDF]
Lumry WR +20 more
europepmc +1 more source

